Literature DB >> 27446405

CD147 modulates androgen receptor activity through the Akt/Gsk-3β/β-catenin/AR pathway in prostate cancer cells.

Fang Fang1, Yingxin Qin2, Feng Hao1, Qiang Li1, Wei Zhang3, Chen Zhao1, Shuang Chen1, Liangzhong Zhao1, Liguo Wang4, Jianhui Cai1.   

Abstract

The androgen signaling pathway serves an important role in the development of prostate cancer. β-Catenin is an androgen receptor (AR) cofactor and augments AR signaling. Glycogen synthase kinase-3β (GSK-3β), a target of phosphorylated serine/threonine protein kinase B (p-Akt), regulates β-catenin stability. In addition, β-catenin, a coregulator of AR, physically interacts with AR and enhances AR-mediated target gene transcription. The multifunctional glycoprotein cluster of differentiation (CD) 147 is highly expressed on the cell surface of the majority of cancer cells, and it promotes tumor invasion, metastasis and growth. In the present study, the molecular effects of CD147 on the Akt/GSK-3β/β-catenin/AR signaling network were investigated in LNCaP cells. Using short hairpin-mediated RNA knockdown of CD147 in LNCaP cells, it was demonstrated that downregulation of CD147 resulted in inhibitory phosphorylation of GSK-3β, and then promoted degeneration of β-catenin and reduced nuclear accumulation of β-catenin. In addition, immunoprecipitation studies demonstrated that CD147 downregulation decreased the formation of a complex between β-catenin and AR. It was shown that CD147 knockdown suppressed the expression of the AR target gene prostate-specific antigen and the growth of AR-positive LNCaP cells. Furthermore, inhibition of PI3K/Akt with LY294002 augmented CD147-mediated function. The present study indicates that the PI3K/Akt pathway may facilitate CD147-mediated activation of the AR pathway.

Entities:  

Keywords:  Akt; CD147; GSK-3β; androgen receptor; proliferation; prostate cancer; prostate-specific antigen; β-catenin

Year:  2016        PMID: 27446405      PMCID: PMC4950659          DOI: 10.3892/ol.2016.4684

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

Review 1.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

2.  Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.

Authors:  Chunming Liu; Yiming Li; Mikhail Semenov; Chun Han; Gyeong Hun Baeg; Yi Tan; Zhuohua Zhang; Xinhua Lin; Xi He
Journal:  Cell       Date:  2002-03-22       Impact factor: 41.582

Review 3.  Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs.

Authors:  Fumi Takahashi-Yanaga; Toshiyuki Sasaguri
Journal:  J Pharmacol Sci       Date:  2009-01-29       Impact factor: 3.337

Review 4.  CD147: regulator of hyaluronan signaling in invasiveness and chemoresistance.

Authors:  G Daniel Grass; Lu Dai; Zhiqiang Qin; Chris Parsons; Bryan P Toole
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

5.  CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma.

Authors:  Yoshio Ishibashi; Tomoe Matsumoto; Mikio Niwa; Yutaka Suzuki; Nobuo Omura; Nobuyoshi Hanyu; Koji Nakada; Katsuhiko Yanaga; Kyosuke Yamada; Kiyoshi Ohkawa; Makio Kawakami; Mitsuyoshi Urashima
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

6.  Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.

Authors:  Q Zhu; H Youn; J Tang; O Tawfik; K Dennis; P F Terranova; J Du; P Raynal; J B Thrasher; B Li
Journal:  Oncogene       Date:  2008-03-31       Impact factor: 9.867

7.  Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase.

Authors:  Geng Wu; Guozhou Xu; Brenda A Schulman; Philip D Jeffrey; J Wade Harper; Nikola P Pavletich
Journal:  Mol Cell       Date:  2003-06       Impact factor: 17.970

8.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.

Authors:  W D Tilley; G Buchanan; T E Hickey; J M Bentel
Journal:  Clin Cancer Res       Date:  1996-02       Impact factor: 12.531

9.  Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer.

Authors:  Sebastian Szubert; Dariusz Szpurek; Rafal Moszynski; Michal Nowicki; Andrzej Frankowski; Stefan Sajdak; Slawomir Michalak
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-28       Impact factor: 4.553

Review 10.  Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  J A McCubrey; L S Steelman; F E Bertrand; N M Davis; S L Abrams; G Montalto; A B D'Assoro; M Libra; F Nicoletti; R Maestro; J Basecke; L Cocco; M Cervello; A M Martelli
Journal:  Leukemia       Date:  2013-06-19       Impact factor: 11.528

View more
  5 in total

1.  Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy.

Authors:  Joshua Hofbauer; Andreas Hauck; Carina Matos; Nathalie Babl; Sonja-Maria Decking; Michael Rechenmacher; Christian Schulz; Sabine Regotta; Marion Mickler; Sebastian Haferkamp; Peter J Siska; Wolfgang Herr; Kathrin Renner; Marina Kreutz; Annette Schnell
Journal:  Biomolecules       Date:  2022-05-18

2.  Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.

Authors:  Frank Jacobsen; Juliane Kraft; Cornelia Schroeder; Claudia Hube-Magg; Martina Kluth; Dagmar S Lang; Ronald Simon; Guido Sauter; Jakob R Izbicki; Till S Clauditz; Andreas M Luebke; Andrea Hinsch; Waldemar Wilczak; Corinna Wittmer; Franziska Büscheck; Doris Höflmayer; Sarah Minner; Maria Christina Tsourlakis; Hartwig Huland; Markus Graefen; Lars Budäus; Imke Thederan; Georg Salomon; Thorsten Schlomm; Nathaniel Melling
Journal:  Neoplasia       Date:  2017-08-19       Impact factor: 5.715

3.  CD147 promotes collective invasion through cathepsin B in hepatocellular carcinoma.

Authors:  Shi-Jie Wang; Dong Chao; Wei Wei; Gang Nan; Jia-Yue Li; Fen-Ling Liu; Ling Li; Jian-Li Jiang; Hong-Yong Cui; Zhi-Nan Chen
Journal:  J Exp Clin Cancer Res       Date:  2020-07-29

4.  CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting.

Authors:  Kai Lu; Zheng Li; Qiang Hu; Jianfei Sun; Ming Chen
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

5.  Exploring the Pharmacological Mechanisms of Xihuang Pills Against Prostate Cancer via Integrating Network Pharmacology and Experimental Validation In Vitro and In Vivo.

Authors:  Yongrong Wu; Xujun You; Qunfang Lin; Wei Xiong; Yinmei Guo; Zhen Huang; Xinjun Dai; Zhengjia Chen; Si Mei; Yan Long; Xuefei Tian; Qing Zhou
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.